 SEATTLE, WA ACCESSWIRE April 14, 2020 Aptevo Therapeutics Inc. APVO, a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM bispecific technology platform, today announced that it has received notice from The NASDAQ Stock Market LLC NASDAQ on April 13, 2020 informing Aptevo that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550a2 for continued listing on The NASDAQ Capital Market. Consequently, Aptevo is now in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market. 